Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kronos Bio, Inc. - Common Stock (NQ: KRON )

0.9850 -0.0200 (-1.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 223,073
Open 0.9932
Bid (Size) 0.9850 (2)
Ask (Size) 0.9851 (1)
Prev. Close 1.005
Today's Range 0.9501 - 0.9932
52wk Range 0.6900 - 1.600
Shares Outstanding 56,769,091
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul
Kronos Bio announces major leadership changes and an 83% workforce reduction as part of a strategic overhaul, with stock gaining in premarket. 
Via Benzinga
Kronos Bio Announces CEO Transition and Reduction in Force
From Kronos Bio, Inc.
Via GlobeNewswire

Performance

YTD
+1.54%
+1.54%
1 Month
-7.94%
-7.94%
3 Month
+4.20%
+4.20%
6 Month
-21.83%
-21.83%
1 Year
-19.26%
-19.26%

More News

Read More
Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining
Via Benzinga
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
Via Benzinga
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in Medical and Investor Conferences in September
From Kronos Bio, Inc.
Via GlobeNewswire
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
From Kronos Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
From Kronos Bio, Inc.
Via GlobeNewswire
KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Kronos Bio Reports First-Quarter 2024 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.